Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by van Staa, T. P.
Right arrow Articles by Cooper, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Staa, T. P.
Right arrow Articles by Cooper, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

The British Journal of Rheumatology, Vol 37, 87-94, Copyright © 1998 by British Society for Rheumatology

ORIGINAL PAPERS

Use of cyclical etidronate and prevention of non-vertebral fractures

TP van Staa, L Abenhaim and C Cooper
Procter & Gamble Pharmaceuticals, Staines.

This study examined the effects of cyclical etidronate, when used in routine clinical practice, on the prevention of fracture. Information was obtained from 550 general practices in the UK that provide their medical records to the General Practice Research Database. A total of 7977 patients taking cyclical etidronate treatment and 7977 age-, sex- and practice-matched control patients with a diagnosis of osteoporosis were analysed. People taking cyclical etidronate had a significantly reduced risk of non-vertebral fracture (by 20%) and of hip fracture (by 34%) relative to the osteoporosis control patients. The relative risk of non-vertebral fracture was 0.80 (95% confidence interval 0.70-0.92), that of hip fracture 0.66 (0.51-0.85) and that of wrist fracture 0.81 (0.58-1.14). When fracture incidence rates were compared between the two groups, the rate of non-vertebral, hip and wrist fracture decreased significantly (P < 0.05) with increasing etidronate exposure. The results of this study complement and extend clinical observations supporting the anti-fracture efficacy of cyclical etidronate therapy.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 PediatricsHome page
R. G. G. Russell
Bisphosphonates: Mode of Action and Pharmacology
Pediatrics, March 1, 2007; 119(Supplement_2): S150 - S162.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
A. B. Hodsman, D. A. Hanley, and R. Josse
Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date
Can. Med. Assoc. J., May 1, 2002; 166(11): 1426 - 1430.
[Full Text] [PDF]

Home page
 QJMHome page
R. Eastell, D.M. Reid, J. Compston, C. Cooper, I. Fogelman, R.M. Francis, S.M. Hay, D.J. Hosking, D.W. Purdie, S.H. Ralston, et al.
Secondary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action?
QJM, November 1, 2001; 94(11): 575 - 597.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
Bisphosphonates for osteoporosis
DTB, September 1, 2001; 39(9): 68 - 72.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
J. E. Compston
Pharmacological interventions for post-menopausal osteoporosis: an evidence-based approach
Rheumatology, December 1, 2000; 39(12): 1309 - 1312.
[Full Text] [PDF]

Home page
 BMJHome page
B. Pal
Questionnaire survey of advice given to patients with fractures
BMJ, February 20, 1999; 318(7182): 500 - 501.
[Full Text]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.